SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-08-12
👔
Latigo Biotherapeutics, Inc.
@LTGO_InsiderForm 4 Filing: Sanofi Acquires shares of $LTGO
INSIDER ACQUISITION
⚡ MATERIALITY: 1/10
corporate issuer
Latigo Biotherapeutics, Inc.
Ticker: $LTGO
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-08-10
Shares: 672,778
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Sanofi, holds the title of 10% Owner at Latigo Biotherapeutics, Inc..
On 2026-08-10, the insider transacted 672,778 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Sanofi (10% Owner) transacted $0 of $LTGO
Post-Transaction Position: 494,800 shares
SEC Accession No: 0001193125-26-345826 (CIK: 1121404)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.